Morgan Stanley
SLN

Morgan Stanley’s Silence Therapeutics SLN Stock Holding History

Morgan Stanley’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.43M Buy
403,172
+337,686
+516% +$2.38M ﹤0.01% 4319
2026
Q1 		$345K Sell
65,486
-259,144
-80% -$1.43M ﹤0.01% 5651
2025
Q4 		$1.97M Sell
324,630
-883,094
-73% -$5.65M ﹤0.01% 4820
2025
Q3 		$6.27M Sell
1,207,724
-4,034
-0.3% -$22.4K ﹤0.01% 3960
2025
Q2 		$7.03M Sell
1,211,758
-788,347
-39% -$3.38M ﹤0.01% 3776
2025
Q1 		$5.64M Buy
2,000,105
+337,037
+20% +$1.65M ﹤0.01% 3826
2024
Q4 		$11.4M Buy
1,663,068
+941,651
+131% +$12.2M ﹤0.01% 3294
2024
Q3 		$13.1M Buy
721,417
+417,424
+137% +$7.77M ﹤0.01% 3213
2024
Q2 		$5.78M Buy
303,993
+61,223
+25% +$1.3M ﹤0.01% 3770
2024
Q1 		$5.24M Buy
242,770
+179,962
+287% +$3.91M ﹤0.01% 3883
2023
Q4 		$1.09M Buy
62,808
+9,511
+18% +$107K ﹤0.01% 4877
2023
Q3 		$523K Sell
53,297
-12,309
-19% -$90.8K ﹤0.01% 5146
2023
Q2 		$361K Sell
65,606
-7,071
-10% -$42.6K ﹤0.01% 5380
2023
Q1 		$451K Sell
72,677
-138,296
-66% -$1.63M ﹤0.01% 5315
2022
Q4 		$3.22M Buy
210,973
+55,814
+36% +$731K ﹤0.01% 4125
2022
Q3 		$1.56M Buy
155,159
+1,866
+1% +$19.6K ﹤0.01% 4601
2022
Q2 		$1.82M Buy
153,293
+1,627
+1% +$19.8K ﹤0.01% 4608
2022
Q1 		$2.88M Sell
151,666
-15,188
-9% -$303K ﹤0.01% 4236
2021
Q4 		$3.99M Buy
166,854
+156,239
+1,472% +$3.62M ﹤0.01% 3954
2021
Q3 		$218K Buy
10,615
+1,050
+11% +$25.1K ﹤0.01% 5956
2021
Q2 		$250K Sell
9,565
-553
-5% -$14.4K ﹤0.01% 5897
2021
Q1 		$233K Buy
10,118
+8,118
+406% +$197K ﹤0.01% 5572
2020
Q4 		$44K Hold
2,000
– – ﹤0.01% 6196
2020
Q3 		$32K Buy
+2,000
New +$37K ﹤0.01% 5881

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Morgan Stanley's SLN Position: Q2 2026 in Review

Morgan Stanley increased its Silence Therapeutics (SLN) stake by 516% in Q2 2026, buying an estimated $2.38M and bringing the position to 403,172 shares worth $4.43M. The position accounts for ﹤0.01% of the portfolio, ranked #4319.

Morgan Stanley first reported a position in SLN in Q3 2020 and has held it in 24 quarters since. The position peaked at $13.1M in Q3 2024. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Morgan Stanley held 403,172 shares of Silence Therapeutics worth $4.43M as of Q2 2026.
  • Morgan Stanley bought 337,686 Silence Therapeutics shares in Q2 2026, an estimated $2.38M.
  • Silence Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4319 holding.
  • Morgan Stanley first reported a position in Silence Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Morgan Stanley's Silence Therapeutics position peaked at $13.1M in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.